<SEC-DOCUMENT>0001193125-24-038517.txt : 20240216
<SEC-HEADER>0001193125-24-038517.hdr.sgml : 20240216
<ACCEPTANCE-DATETIME>20240216163112
ACCESSION NUMBER:		0001193125-24-038517
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20231207
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240216
DATE AS OF CHANGE:		20240216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vanda Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001347178
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				030491827
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34186
		FILM NUMBER:		24648890

	BUSINESS ADDRESS:	
		STREET 1:		2200 PENNSYLVANIA AVE NW
		STREET 2:		SUITE 300E
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20037
		BUSINESS PHONE:		202-734-3400

	MAIL ADDRESS:	
		STREET 1:		2200 PENNSYLVANIA AVE NW
		STREET 2:		SUITE 300E
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20037
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>d620689d8ka.htm
<DESCRIPTION>8-K/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vnda="http://www.vandapharmaceuticals.com/20231207" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K/A</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-292">true</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-12-07_to_2023-12-07">0001347178</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="vnda-20231207.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2023-12-07_to_2023-12-07"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-07</xbrli:startDate> <xbrli:endDate>2023-12-07</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-303">8-K/A</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Amendment No.&#160;1)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-12-07_to_2023-12-07" format="ixt:datemonthdayyearen" id="ixv-304">December&#160;7, 2023</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-305">VANDA PHARMACEUTICALS INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-12-07_to_2023-12-07" format="ixt-sec:stateprovnameen" id="ixv-306">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-307">001-34186</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-308">03-0491827</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction<br/>of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br/>File No.)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-309">2200 Pennsylvania Avenue NW</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-310">Suite 300E</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-311">Washington</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-312">DC</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-313">20037</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices and zip code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-314">(202)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-315">734-3400</ix:nonNumeric></span></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-12-07_to_2023-12-07" format="ixt-sec:boolballotbox" id="ixv-316">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-12-07_to_2023-12-07" format="ixt-sec:boolballotbox" id="ixv-317">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-12-07_to_2023-12-07" format="ixt-sec:boolballotbox" id="ixv-318">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-12-07_to_2023-12-07" format="ixt-sec:boolballotbox" id="ixv-319">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-320">Common Stock, par value $0.001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-321">VNDA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-12-07_to_2023-12-07" format="ixt-sec:exchnameen" id="ixv-322">The Nasdaq Global Market</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-12-07_to_2023-12-07" format="ixt-sec:boolballotbox" id="ixv-323">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Explanatory Note </p> <ix:nonNumeric name="dei:AmendmentDescription" contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-150"><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Amendment No.&#160;1 on Form <span style="white-space:nowrap">8-K/A</span> (&#8220;Amendment No.&#160;1&#8221;) amends the Current Report on Form <span style="white-space:nowrap">8-K</span> of Vanda Pharmaceuticals Inc. (&#8220;Vanda&#8221;), filed on December&#160;7, 2023 (the &#8220;Original Report&#8221;), in which Vanda reported the acquisition from Actelion Pharmaceuticals Ltd., a Johnson&#160;&amp; Johnson Company (&#8220;Janssen&#8221;), of the U.S. and Canadian rights for PONVORY<sup style="font-size:75%; vertical-align:top">&#174;</sup> (ponesimod) (the &#8220;Acquired Business&#8221;), pursuant to the terms of that certain Asset Purchase Agreement, dated as of December&#160;7, 2023 by and between Vanda and Janssen.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Amendment No.&#160;1 is being filed by Vanda to amend the Original Report solely to provide the financial statement and financial information required by Item 9.01 of Form <span style="white-space:nowrap">8-K</span> that were not filed with the Original Report.</p> </ix:nonNumeric> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Financial Statements of Business Acquired. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The audited special purpose abbreviated financial statements for the Acquired Business as of and for the years ended January&#160;1, 2023 and January&#160;2, 2022 and the unaudited special purpose abbreviated financial statements for the Acquired Business as of and for the nine months ended October&#160;1, 2023 and October&#160;2, 2022 are filed as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form <span style="white-space:nowrap">8-K</span> and incorporated in this Item 9.01(a) by reference. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pro Forma Financial Information </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements for the year ended December&#160;31, 2023 giving effect to the acquisition of the Acquired Business are filed as Exhibit 99.3 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and incorporated in this Item 9.01(b) by reference. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Exhibits </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;No.&#8195;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d620689dex231.htm">Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d620689dex991.htm">Audited Special Purpose Abbreviated Financial Statements for the Acquired Business as of and for the years ended January&#160;1, 2023 and January&#160;2, 2022. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d620689dex992.htm">Unaudited Special Purpose Abbreviated Financial Statements for the Acquired Business as of and for the nine months ended October&#160;1, 2023 and October&#160;2, 2022. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d620689dex993.htm">Unaudited pro forma condensed combined financial information for the year ended December&#160;31, 2023. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Dated: February&#160;16, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">VANDA PHARMACEUTICALS INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Timothy Williams</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Timothy Williams</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Senior Vice President, General Counsel and Secretary</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d620689dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT AUDITORS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby
consent to the incorporation by reference in the Registration Statements on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (No. <FONT STYLE="white-space:nowrap">333-269654)</FONT> and Form <FONT STYLE="white-space:nowrap">S-8</FONT> (No. <FONT
STYLE="white-space:nowrap">333-133368,</FONT> No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">333-138070,No.&nbsp;333-141571,</FONT></FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-148924,</FONT> <FONT
STYLE="white-space:nowrap">No.&nbsp;333-156995,</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-164567,</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-171962,</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-179265,</FONT> <FONT
STYLE="white-space:nowrap">No.&nbsp;333-186509,</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-193614,</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-201754,</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-209144,</FONT> <FONT
STYLE="white-space:nowrap">No.&nbsp;333-212255,</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-218774,</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-225599,</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-239103,</FONT> <FONT
STYLE="white-space:nowrap">No.&nbsp;333-256994,</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-265692,</FONT> and <FONT STYLE="white-space:nowrap">No.&nbsp;333-272522)</FONT> of Vanda Pharmaceuticals Inc. of our report dated February&nbsp;12,
2024 relating to the financial statements of the PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Product Line of Actelion Pharmaceuticals, Ltd., which appears in this Current Report on Form
<FONT STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Florham Park, New Jersey </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;16, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d620689dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>PECIAL</SMALL> P<SMALL>URPOSE</SMALL> A<SMALL>BBREVIATED</SMALL> F<SMALL>INANCIAL</SMALL> S<SMALL>TATEMENTS</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Product Line </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(A Product Line of Actelion Pharmaceuticals Ltd.) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">As of and for the Years Ended January&nbsp;1, 2023 and January&nbsp;2, 2022 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Product Line </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Special Purpose Abbreviated Financial Statements </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">As of and for the Years Ended January&nbsp;1, 2023 and January&nbsp;2, 2022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Contents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="98%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Report of Independent Auditors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Special Purpose Abbreviated Financial Statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statements of Assets Acquired as of January&nbsp;1, 2023 and January&nbsp;2, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statements of Revenues and Direct Expenses for the fiscal years ended January&nbsp;1, 2023 and
January&nbsp;2,2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes to the Special Purpose Abbreviated Financial Statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Report of Independent Auditors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Management of Johnson&nbsp;&amp; Johnson<B> </B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying special
purpose abbreviated financial statements of the PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Product Line of Actelion Pharmaceuticals, Ltd. (the &#147;Company&#148;), which comprise the special purpose abbreviated statement of
assets acquired as of January&nbsp;1, 2023 and January&nbsp;2, 2022, and the related special purpose abbreviated statement of revenues and direct expenses for the years then ended, including the related notes (collectively referred to as the
&#147;special purpose abbreviated financial statements&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the accompanying special purpose abbreviated financial statements present
fairly, in all material respects, the assets acquired of the PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Product Line of Actelion Pharmaceuticals. Ltd. as of January&nbsp;1, 2023 and January&nbsp;2, 2022, and its revenue and
direct expenses for the years then ended in accordance with accounting principles generally accepted in the United States of America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis for
Opinion </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS). Our
responsibilities under those standards are further described in the Auditors&#146; Responsibilities for the Audit of the Special Purpose Abbreviated Financial Statements section of our report. We are required to be independent of the Company and to
meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emphasis of Matter </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying special
purpose abbreviated financial statements were prepared in connection with Actelion Pharmaceuticals, Ltd.&#146;s divesture of the PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Product Line and, as described in Note 2, were
prepared for the purpose of complying with the rules and regulations of the Securities and Exchange Commission. These special purpose abbreviated financial statements are not intended to be a complete presentation of the financial position, results
of operations or cash flows of the PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Product Line of Actelion Pharmaceuticals, Ltd. Our opinion is not modified with respect to this matter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Responsibilities of Management for the Special Purpose Abbreviated Financial Statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management is responsible for the preparation and fair presentation of the special purpose abbreviated financial statements in accordance with accounting
principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of the special purpose abbreviated financial statements that are
free from material misstatement, whether due to fraud or error. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In preparing the special purpose abbreviated financial statements, management is required
to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#146;s ability to continue as a going concern for one year after the date the special purpose abbreviated<B>
</B>financial statements are available to be issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Auditors&#146; Responsibilities for the Audit of the Special Purpose Abbreviated Financial
Statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our objectives are to obtain reasonable assurance about whether the special purpose abbreviated financial statements as a whole are
free from material misstatement, whether due to fraud or error, and to issue an auditors&#146; report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an
audit conducted in accordance with US GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion,
forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a
reasonable user based on the special purpose abbreviated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In performing an audit in accordance with US GAAS, we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exercise professional judgment and maintain professional skepticism throughout the audit. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Identify and assess the risks of material misstatement of the special purpose abbreviated financial statements,
whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the special purpose abbreviated financial
statements. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are
appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control. Accordingly, no such opinion is expressed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting
estimates made by management, as well as evaluate the overall presentation of the special purpose abbreviated financial statements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise
substantial doubt about the Company&#146;s ability to continue as a going concern for a reasonable period of time. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are required to
communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">/s/PricewaterhouseCoopers LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Florham Park, New Jersey</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">February&nbsp;12, 2024</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Product Line </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Special Purpose Abbreviated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Assets Acquired as of January&nbsp;1, 2023 and January&nbsp;2, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands)</I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible asset, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">513,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Assets Acquired</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>36,844</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>513,479</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying Notes are integral to the Special Purpose Abbreviated Financial Statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Product Line </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Special Purpose Abbreviated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Revenues and Direct Expenses for the fiscal years ended January&nbsp;1, 2023 and January&nbsp;2,2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands)</I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal years ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales to customers, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 17,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of products sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, marketing and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impairment of intangible asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">426,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total direct expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">571,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Direct expenses in excess of sales to customers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(553,737</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(160,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying Notes are integral to the Special Purpose Abbreviated Financial Statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Product Line </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Special Purpose Abbreviated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands)</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1. Background
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Actelion Pharmaceuticals Ltd. (&#147;Actelion&#148;) is a wholly owned subsidiary of Johnson&nbsp;&amp; Johnson (the &#147;Parent&#148; and, together
with its subsidiaries, the &#147;Company&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Actelion has agreed to divest the U.S. and Canadian rights associated with PONVORY<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (ponesimod) (collectively the &#147;Product Line&#148;), which is a daily, oral prescription medicine approved by the U.S. Food and Drug Administration (&#147;FDA&#148;) and Health Canada to
treat adults with relapsing forms of multiple sclerosis (RMS), which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;7, 2023, Actelion executed an asset purchase agreement (the &#147;Agreement&#148;) with Vanda Pharmaceuticals Inc., a Delaware Corporation,
(&#147;Vanda&#148; or &#147;Buyer&#148;) to sell the U.S. and Canadian rights of PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (ponesimod) for a total purchase price of $100&nbsp;million. The Agreement includes the transfer of
patents, trademarks and intellectual property associated with PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. In connection with the Agreement, Actelion and the Buyer have agreed to enter into a transition agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2. Basis of Presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These Special Purpose
Abbreviated Financial Statements as of and for the fiscal years ended January&nbsp;1, 2023 and January&nbsp;2, 2022 (the &#147;Financial Statements&#148;) are derived from the historical accounting records of the Company and only present the assets
acquired and the revenues and direct expenses, including certain allocated direct expenses, of the Product Line. It is impracticable to prepare complete financial statements related to the Product Line as it was not a separate legal entity of the
Company and was never operated as a standalone business, division, segment or subsidiary. The Company has never prepared full stand-alone or full <FONT STYLE="white-space:nowrap">carve-out</FONT> financial statements for the Product Line and has
never maintained distinct and separate accounts necessary to prepare such financial statements. These Financial Statements are based upon the Agreement and relief under SEC Rule <FONT STYLE="white-space:nowrap">3-05(e),</FONT> <I>Financial
statements of businesses acquired or to be acquired</I>, as the acquisition by Vanda meets the qualifying conditions established by the Securities and Exchange Commission to provide abbreviated financial statements in lieu of full financial
statements of the acquired business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Financial Statements have been prepared to reflect the assets acquired by the Buyer in accordance with the
Agreement and include costs directly associated with producing revenues, including a reasonable allocation of direct expenses, and exclude expenses (&#147;Omitted Expenses&#148;) not directly involved in revenue producing activities, such as
corporate overhead unrelated to the operational activities, interest and income tax. Therefore, these Financial Statements are not intended to be a complete presentation of the financial position, results of operations or cash flows of the Product
Line in conformity with accounting principles generally accepted in the United States of America. As the Product Line has historically been managed as part of the operations of the Company and has not been operated as a stand-alone entity,
information about the Product Line operating, investing, and financing cash flows is not available. As such, statements of cash flows are not presented in the Financial Statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The operations of the Product Line rely, to varying degrees, on the Company for marketing, sales order processing, billing, collection, procurement, customer
service, manufacturing, warehousing and distribution, information technology, insurance, human resources, accounting, regulatory, treasury, legal support, and other administrative services, and these expenses have been allocated in these Financial
Statements. The Financial Statements are not indicative of the financial condition or results of operations of the Product Line on a <FONT STYLE="white-space:nowrap">go-forward</FONT> and stand-alone basis because of the exclusion of Omitted
Expenses and reliance of the Product Line on Actelion, the Parent and certain of their affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Financial Statements include an intangible asset
which represents the U.S. and Canadian rights of PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (ponesimod). The intangible asset was acquired through the Parent&#146;s acquisition of Actelion in 2017 at which time the intangible
asset was classified as Purchased <FONT STYLE="white-space:nowrap">In-process</FONT> Research and Development (IPR&amp;D). Upon FDA approval of PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> on March&nbsp;19, 2021, and
commercialization shortly thereafter, the intangible asset began amortizing over its estimated useful life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The operations of the Product Line are
included in the consolidated federal income tax return of the Parent, to the extent appropriate, and are included in the foreign, state and local returns of certain other affiliates of the Parent. A provision for income taxes has not been presented
in these Financial Statements as the Product Line has not operated as a stand-alone entity and no allocation of income tax provision or benefit has been made to the Product Line. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the accounting guidance related to the presentation of financial statements, management evaluates whether there are conditions or events,
considered in the aggregate that may impact the Product Line&#146;s ability to continue as a going concern for the next twelve months from the date the financial statements are available to be issued. The Financial Statements have been prepared
assuming that the Product Line will continue as a going concern, and do not include any adjustments relating to the carrying amounts and classification of assets that may be necessary should the Product Line be unable to continue as a going concern.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Product Line has incurred net losses of $553,737 and $160,345 for the fiscal years ended January&nbsp;1,
2023 and January&nbsp;2, 2022, respectively, as a result of costs incurred to market and promote the Product Line, research and development costs incurred for post-marketing studies and <FONT STYLE="white-space:nowrap">non-cash</FONT> impairment and
amortization charges discussed in Note 5. Cash generated from the Product Line&#146;s operations is managed by the Company&#146;s centralized treasury function and is swept into the Company&#146;s bank accounts. The Company has continued to provide
financing requirements to the Product Line through the date of the sale of the Product Line on December&nbsp;7, 2023 after which time the Buyer has assumed responsibility for financing requirements of the Product Line. Accordingly, the Financial
Statements have been prepared assuming that the Product Line will continue as a going concern. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3. Certain Expenses and Allocations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain costs and expenses, which relate to revenue producing activities, presented in the Financial Statements have been allocated by management to the
Product Line based on a specific identification basis or, when specific identification is not practicable, a proportional cost allocation method, depending on the nature of the services rendered. Management considers that such allocations have been
made on a reasonable basis but may not necessarily be indicative of the costs that would have been incurred if the Product Line had been operated on a stand-alone basis for the fiscal years presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Allocations of corporate overhead cost from the Company unrelated to the operations and revenue producing activities of the Product Line have been excluded
from these Financial Statements for all periods presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cost of products sold include allocations for overhead incurred by the Company on behalf of
the Product Line and primarily relate to compensation for employees, outside services and shared services. Selling, marketing and administrative expenses, represent operating expenses specifically attributable to the Product Line, including costs
such as information technology and administrative costs. These costs are primarily allocated to the Product Line based on revenue or headcount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research
and development costs primarily relate to the global clinical studies of PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. Costs incurred prior to regulatory approval (for which FDA approval occurred in the U.S. on March&nbsp;19,
2021) primarily related to clinical studies evaluating the safety and efficacy of PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>; whereas, costs incurred after regulatory approval primarily related to clinical studies to fulfil
post-approval commitments required by various regulatory authorities. As the Product Line and the Company&#146;s PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> business in other regions benefitted equally from the global clinical
trials, including post-approval commitments, management allocated approximately half of the global worldwide research and development costs incurred by the Company to the Product Line. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs incurred by the Company related to the divestiture of the Product Line have not been included in these Financial Statements. These costs comprise of
employee related costs, legal, audit and consultancy fees and other costs solely related to the divestiture of the Product Line. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4. Summary of
Significant Accounting Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual Closing Date </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Product Line follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. The 2022 and 2021 fiscal years
consist of 52 weeks, but every five or six years the fiscal year consists of 53 weeks. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Use of Estimates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of these Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts
reported. The estimates and associated assumptions are based on historical experience, judgments and various other factors that are believed to be reasonable under the circumstances but are inherently uncertain. The estimation process required to
prepare the Financial Statements, includes but is not limited to, allocation of certain direct costs and expenses from the Parent or other subsidiaries, accounting for deductions from revenue (e.g., rebates, sales discounts, and allowances),
determination of the useful life of the intangible asset and the assessment of expected cash flows used in evaluating the intangible asset for impairment. Actual results may or may not differ from these estimates. Also, as discussed in Note 3, these
Financial Statements include allocations and estimates that are not necessarily indicative of the amounts that would have resulted if the Product Line had been operated on a stand-alone basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recently Adopted Accounting Standards </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no new
material accounting standards adopted in fiscal 2021 or 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recently Issued Accounting Standards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not Adopted as of January&nbsp;1, 2023: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASU <FONT
STYLE="white-space:nowrap">2022-04:</FONT> Liabilities-Supplier Finance Programs (Topic <FONT STYLE="white-space:nowrap">405-50)</FONT> &#150; Disclosure of Supplier Finance Program Obligations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This update requires that a buyer in a supplier finance program disclose additional information about the
program to allow financial statement users to better understand the effect of the programs on an entity&#146;s working capital, liquidity, and cash flows. This update will be effective for the Product Line for fiscal years beginning after
December&nbsp;15, 2022, except for the amendment on roll forward information, which is effective for fiscal years beginning after December&nbsp;15,2023. Early adoption is permitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company adopted the standard as of the beginning of fiscal year 2023, which requires that a buyer in a supplier finance program disclose additional
information about the program for financial statement users. The Product Line does not have agreements for supplier finance programs with third-party financial institutions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Intangible Asset </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Product Line&#146;s intangible
asset represents the U.S. and Canadian rights of PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (ponesimod), which was IPR&amp;D acquired as part of the Parent&#146;s acquisition of Actelion in 2017. The fair value of IPR&amp;D is
capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and
amortized using the straight-line method over the estimated useful life. Accordingly, IPR&amp;D was reclassified to Patents and Trademarks after FDA approval of PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> on March&nbsp;19,
2021, and began amortizing over its estimated useful life. The amortization expense is recorded in &#145;Cost of products sold&#146; in the Financial Statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company reviews its intangible asset for impairment whenever events or changes in circumstances such as asset utilization, commercial events, legal
factors or other matters indicate that the carrying value of the asset may not be recoverable. The impairment testing involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows. In the event the carrying
value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset&#146;s carrying value over its fair value, calculated
using discounted future cash flows. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue Recognition </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Product Line recognizes revenue in line with the Company&#146;s policies and procedures. Revenue is recognized from product sales when obligations under
the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company&#146;s global payment terms are typically between 30 to 90 days. Provisions for certain rebates,
sales incentives, product returns, discounts to customers and governmental programs are accounted for as variable consideration and recorded as a reduction in sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions. Rebates
are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions. Rebates primarily relate to Managed Care, Medicare and Medicaid programs. The Product Line evaluates market conditions
primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product
recall. Sales returns are estimated and recorded based on historical sales and returns information. In accordance with the Company&#146;s accounting policies, the Product Line issues credit to customers for returned goods. The Product Line&#146;s
sales returns reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns are generally not resalable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reconciliation of gross sales to customers to sales to customers, net by each significant category of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">gross-to-net</FONT></FONT> adjustments was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal years ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross sales to customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Gross-to-net</FONT></FONT>
adjustments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rebates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales returns&nbsp;&amp; other discounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gross-to-net</FONT></FONT>
adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Sales to customers, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17,837</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,855</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shipping and Handling </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shipping and handling costs incurred were $77 and $17 for the fiscal years ended January&nbsp;1, 2023 and January&nbsp;2, 2022 and are included in
&#145;Selling, marketing and administrative expenses&#146; in the Financial Statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All costs associated with research and development activities are expensed as incurred. Research and development costs incurred prior to regulatory approval
(for which FDA approval occurred in the U.S. on March&nbsp;19, 2021) primarily related to global clinical studies evaluating the safety and efficacy of PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>; whereas, costs incurred after
regulatory approval primarily related to clinical studies for post-approval commitments required by various regulatory bodies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advertising </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs associated with advertising are expensed in the fiscal year incurred and are included in &#145;Selling, marketing, and administrative expenses&#146; on
these Statements of Revenues and Direct Expenses. Such expenses were $17,721 and $45,559 for the fiscal years ended January&nbsp;1, 2023 and January&nbsp;2, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Based Compensation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain eligible employees of
the Company have been awarded stock option grants or restricted stock units under the Company&#146;s stock option plans. These stock options and restricted stock grants are accounted for under the fair value method of equity-based compensation
accounting principles and have been recognized in these Financial Statements. Stock based compensation expense recognized was $371 and $352 for the fiscal years ended January&nbsp;1, 2023 and January&nbsp;2, 2022. Certain eligible employees of the
Company also participated in various other Company benefit plans, as described in Note 6. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Concentration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In fiscal year 2022, the Product Line utilized four specialty distributors that represented approximately 42%, 25%, 18% and 15% of gross revenues,
respectively. In fiscal year 2021, the Company utilized the same four specialty distributors that represented approximately 40%, 22%, 18% and 20% of gross revenues, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5. Intangible asset, net </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of January&nbsp;1, 2023
and January&nbsp;2, 2022 the gross and net amounts of the intangible asset were: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross carrying amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">555,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">555,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: impairment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">426,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Intangible asset, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 36,844</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>513,479</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The intangible asset represents the U.S. and Canadian rights of
PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. The intangible asset was acquired through the Parent&#146;s acquisition of Actelion in 2017 at which time the intangible asset was classified as
<FONT STYLE="white-space:nowrap">In-process</FONT> Research and Development (IPR&amp;D). Upon FDA approval of PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> on March&nbsp;19, 2021, and commercialization shortly thereafter, the
intangible asset began amortizing over its estimated useful life of 11 years for which as of January&nbsp;1, 2023 there are 9 years remaining. The amortization expense recognized was $50,506 and $42,088 for the fiscal years ended January&nbsp;1,
2023, and January&nbsp;2, 2022, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Carrying amount changes from fiscal year 2021 to fiscal year 2022 are driven by impairment charges.
Intangible assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in
&#145;Impairment of intangible asset&#146; in the Statements of Revenues and Direct Expenses. The Product Line continues to monitor the recoverability of its definite lived intangible asset and tests the asset for impairment if indicators of
impairment are present. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amortization expense for the five succeeding years is approximately $4&nbsp;million per year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Product Line recognized an impairment of $426,129 resulting from the assessment of recoverability of the
asset following the Company&#146;s decision at the end of the fourth quarter in 2022 to reduce commercial support for PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> in the U.S. due to performance of the business to date and is
reflected in &#145;Impairment of intangible asset&#146; within the Financial Statements. In management&#146;s assessment of recoverability and determination of fair value, a discounted cash flow methodology was used which requires significant
judgement and estimation. The fair value measurement was based on Level&nbsp;3 inputs including estimated net sales to customers, cost of products sold, research and development costs, selling and marketing costs and discount rate. While management
believes the assumptions used are reasonable and commensurate with the views of a market participant, changes in key assumptions for the intangible asset, including increasing the discount rate, lowering sales to customers forecasts, lowering the
operating margin, could result in a future impairment. Other market factors and conditions could also result in downward revisions of the forecasts on future projected cash flows of the intangible asset. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6. Employee benefit plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These Financial
Statements include certain employee benefit expenses. These benefits include medical, dental, comprehensive and preventive for active employees, group life insurance and employer match pursuant to the U.S. 401(k) savings plan. These are managed on a
centralized basis by the Company and are calculated using <FONT STYLE="white-space:nowrap">charge-out</FONT> rates for these benefits. The costs and <FONT STYLE="white-space:nowrap">charge-out</FONT> rates are determined annually by the Company for
allocation purposes among its affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the fiscal years ended January&nbsp;1, 2023 and January&nbsp;2, 2022, $1,241 and $574 of employee benefit
expenses are included within these Financial Statements.<B> </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7. Subsequent events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Financial Statements are derived from the accounts of the Company, which issued its most recent annual financial statements on February&nbsp;16, 2023.
Accordingly, the Product Line has evaluated transactions for recognition or disclosure in the annual financial statements through February&nbsp;16, 2023. Additionally, the Product Line has evaluated transactions for purposes of disclosure of
unrecognized subsequent events through February&nbsp;12, 2024, the date these Financial Statements were available to be issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>d620689dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>PECIAL</SMALL> P<SMALL>URPOSE</SMALL> A<SMALL>BBREVIATED</SMALL> F<SMALL>INANCIAL</SMALL> S<SMALL>TATEMENTS</SMALL> (
U<SMALL>NAUDITED</SMALL> ) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Product Line </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(A Product Line of Actelion Pharmaceuticals Ltd.) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Statements of Assets Acquired as of October&nbsp;1, 2023 (Unaudited) and January&nbsp;1, 2023 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Unaudited Statements of Revenues and Direct Expenses for the nine months ended October&nbsp;1, 2023 and October&nbsp;2, 2022 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Product Line </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Special Purpose Abbreviated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Statements of Assets Acquired as of October&nbsp;1, 2023 (Unaudited) and January&nbsp;1, 2023 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Statements of Revenues and Direct Expenses (Unaudited) for the nine months ended October&nbsp;1, 2023 and October 2, 2022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Contents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="98%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Special Purpose Abbreviated Financial Statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statements of Assets Acquired as of October&nbsp;1, 2023 (Unaudited) and January&nbsp;1,
2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statements of Revenues and Direct Expenses (Unaudited) for the nine months ended October&nbsp;1,
2023 and October&nbsp;2, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes to the Special Purpose Abbreviated Financial Statements (Unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Product Line </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Special Purpose Abbreviated Financial Statements (Unaudited) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Assets Acquired as of October&nbsp;1, 2023 (Unaudited) and January&nbsp;1, 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands)</I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible asset, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Assets Acquired</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>33,829</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>36,844</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying Notes are integral to the Special Purpose Abbreviated Financial Statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Product Line </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Special Purpose Abbreviated Financial Statements (Unaudited) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Revenues and Direct Expenses (Unaudited) for the nine months ended October&nbsp;1, 2023 and October&nbsp;2, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands)</I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine months ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales to customers, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;23,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 12,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of products sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, marketing and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total direct expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Direct expenses in excess of sales to customers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;(4,601)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;(99,314)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying Notes are integral to the Special Purpose Abbreviated Financial Statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Product Line </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Special Purpose Abbreviated Financial Statements (Unaudited) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands)</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1. Background
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Actelion Pharmaceuticals Ltd. (&#147;Actelion&#148;) is a wholly owned subsidiary of Johnson&nbsp;&amp; Johnson (the &#147;Parent&#148; and, together
with its subsidiaries, the &#147;Company&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Actelion has agreed to divest the U.S. and Canadian rights associated with PONVORY<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (ponesimod) (collectively the &#147;Product Line&#148;), which is a daily, oral prescription medicine approved by the U.S. Food and Drug Administration (&#147;FDA&#148;) and Health Canada to
treat adults with relapsing forms of multiple sclerosis (RMS), which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;7, 2023, Actelion executed an asset purchase agreement (the &#147;Agreement&#148;) with Vanda Pharmaceuticals Inc., a Delaware Corporation,
(&#147;Vanda&#148; or &#147;Buyer&#148;) to sell the U.S. and Canadian rights of PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (ponesimod) for a total purchase price of $100&nbsp;million. The Agreement includes the transfer of
patents, trademarks and intellectual property associated with PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. In connection with the Agreement, Actelion and the Buyer have agreed to enter into a transition agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2. Basis of Presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These Special Purpose
Abbreviated Statements of Assets Acquired as of October&nbsp;1, 2023 and January&nbsp;1, 2023 and the related Special Purpose Abbreviated Statements of Revenues and Direct Expenses for the nine months ended October&nbsp;1, 2023 and October&nbsp;2,
2022 (collectively the &#147;Financial Statements&#148;) are derived from the historical accounting records of the Company and only present the assets acquired and the revenues and direct expenses, including certain allocated direct expenses, of the
Product Line. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. It
is impracticable to prepare complete financial statements related to the Product Line as it was not a separate legal entity of the Company and was never operated as a standalone business, division, segment or subsidiary. The Company has never
prepared full stand-alone or full <FONT STYLE="white-space:nowrap">carve-out</FONT> financial statements for the Product Line and has never maintained distinct and separate accounts necessary to prepare such financial statements. These Financial
Statements are based upon the Agreement and relief under SEC Rule <FONT STYLE="white-space:nowrap">3-05(e),</FONT> <I>Financial statements of businesses acquired or to be acquired,</I> as the acquisition by Vanda meets the qualifying conditions
established by the Securities and Exchange Commission to provide abbreviated financial statements in lieu of full financial statements of the acquired business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Financial Statements have been prepared to reflect the assets acquired by the Buyer in accordance with the Agreement and include costs directly associated
with producing revenues, including a reasonable allocation of direct expenses, and exclude expenses (&#147;Omitted Expenses&#148;) not directly involved in revenue producing activities, such as corporate overhead unrelated to the operational
activities, interest and income tax. Therefore, these Financial Statements are not intended to be a complete presentation of the financial position, results of operations or cash flows of the Product Line in conformity with accounting principles
generally accepted in the United States of America. As the Product Line has historically been managed as part of the operations of the Company and has not been operated as a stand-alone entity, information about the Product Line operating,
investing, and financing cash flows is not available. As such, statements of cash flows are not presented in the Financial Statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The operations of
the Product Line rely, to varying degrees, on the Company for marketing, sales order processing, billing, collection, procurement, customer service, manufacturing, warehousing and distribution, information technology, insurance, human resources,
accounting, regulatory, treasury, legal support, and other administrative services, and these expenses have been allocated in these Financial Statements. The Financial Statements are not indicative of the financial condition or results of operations
of the Product Line on a <FONT STYLE="white-space:nowrap">go-forward</FONT> and stand-alone basis because of the exclusion of Omitted Expenses and reliance of the Product Line on Actelion, the Parent and certain of their affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Financial Statements include an intangible asset which represents the U.S. and Canadian rights of
PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (ponesimod). The intangible asset was acquired through the Parent&#146;s acquisition of Actelion in 2017 at which time the intangible asset was classified as Purchased <FONT
STYLE="white-space:nowrap">In-process</FONT> Research and Development (IPR&amp;D). Upon FDA approval of PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> on March&nbsp;19, 2021, and commercialization shortly thereafter, the
intangible asset began amortizing over its estimated useful life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The operations of the Product Line are included in the consolidated federal income tax
return of the Parent, to the extent appropriate, and are included in the foreign, state and local returns of certain other affiliates of the Parent. A provision for income taxes has not been presented in these Financial Statements as the Product
Line has not operated as a stand-alone entity and no allocation of income tax provision or benefit has been made to the Product Line. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the accounting guidance related to the presentation of financial statements, management
evaluates whether there are conditions or events, considered in the aggregate, that may impact the Product Line&#146;s ability to continue as a going concern for the next twelve months from the date the financial statements are available to be
issued. The Financial Statements have been prepared assuming that the Product Line will continue as a going concern, and do not include any adjustments relating to the carrying amounts and classification of assets that may be necessary should the
Product Line be unable to continue as a going concern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Product Line has incurred net losses of $4,601 and $99,314 for the nine months ended
October&nbsp;1, 2023 and October&nbsp;2, 2022, respectively, as a result of costs incurred to market and promote the Product Line, research and development costs incurred for post-marketing studies and
<FONT STYLE="white-space:nowrap">non-cash</FONT> amortization charges discussed in Note 4. Cash generated from the Product Line&#146;s operations is managed by the Company&#146;s centralized treasury function and is maintained in the Company&#146;s
bank accounts. The Company has continued to provide financing requirements to the Product Line through the date of the sale of the Product Line on December&nbsp;7, 2023 after which time the Buyer has assumed responsibility for financing requirements
of the Product Line. Accordingly, the Financial Statements have been prepared assuming that the Product Line will continue as a going concern. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3.
Certain Expenses and Allocations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain costs and expenses, which relate to revenue producing activities, presented in the Financial Statements have
been allocated by management to the Product Line based on a specific identification basis or, when specific identification is not practicable, a proportional cost allocation method, depending on the nature of the services rendered. Management
considers that such allocations have been made on a reasonable basis but may not necessarily be indicative of the costs that would have been incurred if the Product Line had been operated on a stand-alone basis for the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Allocations of corporate overhead cost from the Company unrelated to the operations and revenue producing activities of the Product Line have been excluded
from these Financial Statements for all periods presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cost of products sold include allocations for overhead incurred by the Company on behalf of
the Product Line and primarily relate to compensation for employees, outside services and shared services incurred. Cost of products sold and selling, marketing and administrative expenses, represent operating expenses, specifically attributable to
the Product Line, including costs such as information technology and administrative costs. These costs are primarily allocated to the Product Line based on revenue or headcount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs primarily relate to the global clinical studies of PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. Costs
incurred prior to regulatory approval (for which FDA approval occurred in the U.S. on March&nbsp;19, 2021) primarily related to clinical studies evaluating the safety and efficacy of PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>;
whereas, costs incurred after regulatory approval primarily related to clinical studies to fulfil post-approval commitments required by various regulatory authorities. As the Product Line and the Company&#146;s PONVORY<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> business in other regions benefitted equally from the global clinical trials, including post-approval commitments, management allocated approximately half of the global worldwide research and
development costs incurred by the Company to the Product Line. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs incurred by the Company related to the divestiture of the Product Line have not been
included in these Financial Statements. These costs comprise of employee related costs, legal, audit and consultancy fees and other costs solely related to the divestiture of the Product Line. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Use of Estimates </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of these Financial
Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. The estimates and associated assumptions are based on historical experience, judgments and various other factors that are
believed to be reasonable under the circumstances but are inherently uncertain. The estimation process required to prepare the Financial Statements, includes but is not limited to, allocation of certain direct costs and expenses from the Parent or
other subsidiaries, accounting for deductions from revenue (e.g., rebates, sales discounts, and allowances), determination of the useful life of the intangible asset and the assessment of expected cash flows used in evaluating the intangible asset
for impairment. Actual results may or may not differ from these estimates. Also, as discussed in Note 3, these Financial Statements include allocations and estimates that are not necessarily indicative of the amounts that would have resulted if the
Product Line had been operated on a stand-alone basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recently Adopted Accounting Standards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASU <FONT STYLE="white-space:nowrap">2022-04:</FONT> Liabilities-Supplier Finance Programs (Topic <FONT STYLE="white-space:nowrap">405-50)</FONT> &#150;
Disclosure of Supplier Finance Program Obligations The Company adopted the standard as of the beginning of fiscal year 2023, which requires that a buyer in a supplier finance program disclose additional information about the program to allow
financial statement users to better understand the effect of the programs on an entity&#146;s working capital, liquidity, and cash flows. The Product Line does not have agreements for supplier finance programs with third-party financial
institutions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recently Issued Accounting Standards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no new material accounting standards issued in the nine months ended October&nbsp;1, 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Intangible Asset </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Product Line&#146;s intangible
asset represents the U.S. and Canadian rights of PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (ponesimod), which was IPR&amp;D acquired as part of the Parent&#146;s acquisition of Actelion in 2017. The fair value of IPR&amp;D is
capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and
amortized using the straight-line method over the estimated useful life. Accordingly, IPR&amp;D was reclassified to Patents and Trademarks after FDA approval of PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> on March&nbsp;19,
2021, and began amortizing over its estimated useful life of 11 years. The amortization expense is recorded in &#145;Cost of products sold&#146; in the Financial Statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company reviews its intangible asset for impairment whenever events or changes in circumstances such as asset utilization, commercial events, legal
factors or other matters indicate that the carrying value of the asset may not be recoverable. The impairment testing involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows. In the event the carrying
value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset&#146;s carrying value over its fair value, calculated
using discounted future cash flows. The Product Line recognized an impairment of $426,129 resulting from the assessment of recoverability of the asset following the Company&#146;s decision at the end of the fourth quarter in 2022 to reduce
commercial support for PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> in the U.S. due to the performance of the business to date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible asset amortization expense was $3,015 and $37,881 for the nine months ended October&nbsp;1, 2023, and October&nbsp;2, 2022, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue Recognition </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Product Line recognizes revenue
in line with the Company&#146;s policies and procedures. Revenue is recognized from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to
customers. The Company&#146;s global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, product returns, discounts to customers and governmental programs are accounted for as variable consideration
and recorded as a reduction in sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Product discounts granted are based on the terms of arrangements with direct, indirect and other market
participants, as well as market conditions. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions. Rebates primarily relate to Managed Care, Medicare and Medicaid
programs. The Product Line evaluates market conditions primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product
recall. Sales returns are estimated and recorded based on historical sales and returns information. In accordance with the Company&#146;s accounting policies, the Product Line issues credit to customers for returned goods. The Product Line&#146;s
sales returns reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns are generally not resalable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reconciliation of gross sales to customers to sales to customers, net by each significant category of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">gross-to-net</FONT></FONT> adjustments was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine months ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross sales to customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Gross-to-net</FONT></FONT>
adjustments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rebates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales returns&nbsp;&amp; other discounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gross-to-net</FONT></FONT>
adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Sales to customers, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,684</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,266</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shipping and Handling </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shipping and handling costs incurred were $102 and $53 for the nine months ended October&nbsp;1, 2023 and October&nbsp;2, 2022, and are included in
&#145;Selling, marketing and administrative expenses&#146; in the Financial Statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All costs associated with research and development activities are expensed as incurred. Research and development costs incurred prior to regulatory approval
(for which FDA approval occurred in the U.S. on March&nbsp;19, 2021) primarily related to global clinical studies evaluating the safety and efficacy of PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>; whereas, costs incurred after
regulatory approval primarily related to clinical studies for post-approval commitments required by various regulatory bodies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advertising </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs associated with advertising are expensed in the fiscal year incurred and are included in &#146;Selling, marketing, and administrative expenses&#146; on
these Statements of Revenues and Direct Expenses. Such expenses were $1,431 and $16,514 for the nine months ended October&nbsp;1, 2023 and October&nbsp;2, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Based Compensation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain eligible employees of
the Company have been awarded stock option grants or restricted stock units under the Company&#146;s stock option plans. These stock options and restricted stock grants are accounted for under the fair value method of equity-based compensation
accounting principles and have been recognized in these Financial Statements. Stock based compensation expense recognized was $145 and $278 for the nine months ended October&nbsp;1, 2023 and October&nbsp;2, 2022. Certain eligible employees of the
Company also participated in various other Company benefit plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Concentration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the fiscal nine months ended October&nbsp;1 2023, the Product Line utilized four specialty distributors that represented approximately 41%, 27%, 20% and 12%
of gross revenues, respectively. In the fiscal nine months ended October&nbsp;2, 2022, the Company utilized the same four specialty distributors that represented approximately 42%, 27%, 13% and 18% of gross revenues, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5. Subsequent events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Financial Statements are
derived from the accounts of the Company, which issued its financial statements for the fiscal nine months ended October&nbsp;1, 2023 on October&nbsp;27, 2023. Accordingly, the Product Line has evaluated transactions for recognition or disclosure in
these Financial Statements through October&nbsp;27, 2023. Additionally, the Product Line has evaluated transactions for purposes of disclosure of unrecognized subsequent events through February&nbsp;12, 2024, the date these Financial Statements were
available to be issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>5
<FILENAME>d620689dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VANDA PHARMACEUTICALS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS (unaudited) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;7, 2023, Vanda Pharmaceuticals Inc. (Vanda or the Company) entered into an Asset Purchase Agreement to acquire certain assets
comprising the exclusive rights to market and sell PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> within the United States (U.S.) and Canada (Ponvory or Purchased Assets) from Actelion Pharmaceuticals Ltd. (Janssen), a
Johnson&nbsp;&amp; Johnson Company, and the closing of the transaction took place simultaneously with signing (the Acquisition). PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a once-daily oral selective <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sphingosine-1-phosphate</FONT></FONT> receptor 1 modulator, indicated to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome,
relapsing-remitting disease and active secondary progressive disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma information presented herein consists of unaudited
pro forma condensed combined statements of operations for the year ended December&nbsp;31, 2023. The presentation of the unaudited pro forma condensed combined statements of operations for the year ended December&nbsp;31, 2023 reflects the combined
results as if the Acquisition had occurred on January&nbsp;1, 2023, the beginning of the Company&#146;s 2023 fiscal year. Ponvory&#146;s historical financial statements of the Purchased Assets as included in these unaudited pro forma condensed
combined financial statements include activities from January&nbsp;2, 2023 through the December&nbsp;7, 2023 date of acquisition. The one day difference in fiscal year start date was not material for adjustment in these unaudited pro forma condensed
combined financial statements. Ponvory&#146;s balance sheet has already been reflected in the Consolidated Balance Sheet of the Company in the annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (Annual Report) for the fiscal year
ended December&nbsp;31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements include adjustments that reflect the
accounting for the Acquisition in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The transaction accounting adjustments consist of those necessary to account for the Acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in Note 2 to the unaudited pro forma condensed combined financial statements, the Company has concluded, in accordance with U.S.
GAAP, that the Acquisition does not meet the definition of a business. However, for purposes of this Form <FONT STYLE="white-space:nowrap">8-K/A,</FONT> and in accordance with <FONT STYLE="white-space:nowrap">S-X</FONT> <FONT
STYLE="white-space:nowrap">11-01,</FONT> the Acquisition is considered the purchase of a business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed
combined financial statements should be read in conjunction with (i)&nbsp;the historical financial statements of the Company included in its Annual Report for the year ended December&nbsp;31, 2023 filed with the SEC on February&nbsp;8, 2024 and
(ii)&nbsp;the Special Purpose Abbreviated Financial Statements of Ponvory as of and for the years ended January&nbsp;1, 2023 and January&nbsp;2, 2022, and as of October&nbsp;1, 2023 and for the nine months ended October&nbsp;1, 2023 and
October&nbsp;2, 2022, included in Exhibits 99.1 and 99.2 of this Form <FONT STYLE="white-space:nowrap">8-K/A.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro
forma condensed combined financial statements are provided for informational purposes only and are not necessarily indicative of results that would have occurred had the Acquisition been completed as of the date indicated. In addition, the unaudited
pro forma condensed combined financial statements do not purport to be indicative of the future financial position or operating results of the combined operations. Actual financial conditions and results of operations may differ significantly from
the pro forma amounts reflected herein due to a variety of factors. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VANDA PHARMACEUTICALS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS (Unaudited) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the year ended December&nbsp;31, 2023 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B><I>(in thousands, except for share and per share amounts)</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vanda<BR>(Historical)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ponvory<BR>(Historical) for<BR>the Nine<BR>Months Ended<BR>October&nbsp;1, 2023<BR>Adjusted for<BR>Reclassifications<BR>(Note 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ponvory<BR>(Historical) for<BR>the Period<BR>October&nbsp;2, 2023<BR>to December&nbsp;7,<BR>2023 Adjusted<BR>for<BR>Reclassifications<BR>(Note 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Condensed<BR>Combined</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net product sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 192,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 221,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">192,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">221,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold excluding amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible asset amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2a</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">206,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">242,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,952</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,753</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,921</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,753</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(630</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision (benefit) for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2b</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,902</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,380,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,380,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,557,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,380,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to unaudited pro forma condensed combined financial information. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VANDA PHARMACEUTICALS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS (Unaudited) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Basis of Presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited
pro forma condensed combined financial information and related notes are prepared in accordance with Article 11 of Regulation <FONT STYLE="white-space:nowrap">S-X.</FONT> The Company and Ponvory&#146;s financial statements included in the unaudited
pro forma condensed combined financial statements have been prepared in accordance with U.S. GAAP. The historical financial statements have been adjusted in the unaudited pro forma condensed combined financial statements to give effect to pro forma
events that reflect the accounting for the Acquisition in accordance with U.S. GAAP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial
statements have been prepared in a manner consistent with the accounting policies adopted by the Company. The accounting policies of PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> have been determined to be similar in all material
respects to the Company&#146;s accounting policies. Other than the reclassification discussed below, no adjustments for accounting policy differences have been reflected in the unaudited pro forma condensed combined financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Transaction Accounting and Reclassification Adjustments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounted for the Acquisition as an asset acquisition in accordance with ASC <FONT STYLE="white-space:nowrap">805-50</FONT> because
substantially all of the fair value of the assets acquired is concentrated in a single asset, the PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> product rights. The PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>
products rights consist of certain patents and trademarks, regulatory approvals, marketing assets, and other records, and are considered a single asset as they are inextricably linked. The total consideration for the acquisition was
$104.9&nbsp;million consisting of cash paid to Janssen and acquisition-related transaction costs, of which $4.2&nbsp;million of the consideration was accrued as of December&nbsp;31, 2023. The total consideration was fully allocated to the acquired
intangible asset for the U.S. and Canada rights to PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Purchase
Agreement includes customary representations, warranties and covenants, as well as standard mutual indemnities covering losses arising from any material breach of the Purchase Agreement or inaccuracy of representations and warranties. Janssen has
agreed to indemnify the Company against losses arising from its activities prior to the closing, and the Company has agreed to indemnify Janssen against losses arising from the Company&#146;s activities pertaining to PONVORY<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> after the closing. Simultaneously and in connection with the Purchase Agreement, the parties have also entered into certain supporting agreements, including a customary transition agreement,
pursuant to which, during a transition period, Janssen will continue PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> operations and the Company and Janssen will transition regulatory and supply responsibility for PONVORY<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> to the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reclassification adjustments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amortization expense for the Ponvory intangible asset of $3.0&nbsp;million for the nine months ended October&nbsp;1, 2023 and
$0.7&nbsp;million for the period from October&nbsp;2, 2023 to December&nbsp;7, 2023 has been reclassified from the cost of goods sold line to the intangible asset amortization line to conform to the Company&#146;s financial statement presentation.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Adjustments to Unaudited Pro Forma Condensed Combined Statements of Operations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(2a) Intangible asset amortization </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> intangible asset is being amortized on a straight-line basis through 2035, which is the estimated economic useful life of the related product rights. The table below reflects the
adjustment to eliminate the historical intangible asset amortization expense and record the new intangible asset amortization expense. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B><I>(in thousands)</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of PONVORY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> product
rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 7,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reversal of historical Ponvory amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,763</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(2b) Income tax provision (benefit) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma presentation of the effect on income tax provision (benefit) was calculated using a U.S. estimated statutory rate of 22.4%. The
adjustments are summarized in the following table. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B><I>(in thousands, except for statutory tax rate)</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Loss&nbsp;before<BR>income&nbsp;taxes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Statutory&nbsp;tax&nbsp;rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Income&nbsp;tax&nbsp;benefit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ponvory historical</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(719</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction accounting adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,753</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>vnda-20231207.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 2/16/2024 11:32:14 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:vnda="http://www.vandapharmaceuticals.com/20231207"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.vandapharmaceuticals.com/20231207"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20231207_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20231207_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>vnda-20231207_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 2/16/2024 11:32:14 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:type="locator" xlink:label="dei_AmendmentDescription" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Description</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Description</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>vnda-20231207_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 2/16/2024 11:32:14 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="vnda-20231207.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:type="locator" xlink:label="dei_AmendmentDescription" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentDescription" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140575525192816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 07, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001347178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  07,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VANDA PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">03-0491827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2200 Pennsylvania Avenue NW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300E<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Washington<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(202)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">734-3400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VNDA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">This Amendment No.&#160;1 on Form 8-K/A (&#8220;Amendment No.&#160;1&#8221;) amends the Current Report on Form 8-K of Vanda Pharmaceuticals Inc. (&#8220;Vanda&#8221;), filed on December&#160;7, 2023 (the &#8220;Original Report&#8221;), in which Vanda reported the acquisition from Actelion Pharmaceuticals Ltd., a Johnson&#160;& Johnson Company (&#8220;Janssen&#8221;), of the U.S. and Canadian rights for PONVORY&#174; (ponesimod) (the &#8220;Acquired Business&#8221;), pursuant to the terms of that certain Asset Purchase Agreement, dated as of December&#160;7, 2023 by and between Vanda and Janssen. This Amendment No.&#160;1 is being filed by Vanda to amend the Original Report solely to provide the financial statement and financial information required by Item 9.01 of Form 8-K that were not filed with the Original Report. <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MIR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%
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M>FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X<L-03&IAJ
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " #B@U!8F5R<(Q &  "<)P  $P
M            @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M .*#4%A.61LM% 8  "<5   8              " @0T(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " #B@U!8GZ ;\+$"  #B#   #0
M            @ %7#@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .*#4%B7
MBKL<P    !,"   +              "  3,1  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( .*#4%@<.&7J/P$  #P"   /              "  1P2  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " #B@U!8)!Z;HJT   #X 0  &@
M        @ &($P  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " #B@U!899!YDAD!  #/ P  $P              @ %M%   6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  "W%0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d620689d8ka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K/A" isOnlyDei="true" original="d620689d8ka.htm">d620689d8ka.htm</File>
    <File>vnda-20231207.xsd</File>
    <File>vnda-20231207_lab.xml</File>
    <File>vnda-20231207_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d620689d8ka.htm": {
   "nsprefix": "vnda",
   "nsuri": "http://www.vandapharmaceuticals.com/20231207",
   "dts": {
    "inline": {
     "local": [
      "d620689d8ka.htm"
     ]
    },
    "schema": {
     "local": [
      "vnda-20231207.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "vnda-20231207_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vnda-20231207_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2023-12-07_to_2023-12-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d620689d8ka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2023-12-07_to_2023-12-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d620689d8ka.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "terseLabel": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.vandapharmaceuticals.com//20231207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-24-038517-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-038517-xbrl.zip
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M/WEF% PTI@+"[I%3I6YFSD%]N0.4"+".MO):D?'W;$D6.:,HS8*Z Q,,8?C
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MKL(%XO3DZ/UBTQ/ .4$Q#*/@<'WA,<6'PCF8PE #-XMAM5]"!2)/J0ED636
M(T 4#%4$+PW  )8!!30V8#L!Z802% $HJL:=9#K4>4CP_IV#AAD,67Q4H QQ
MRST6/(#)&I\%?A-CZ1'+)KJ_N#T6@N][#/5C1&T :00=X$*S@,;(#'FAO&?N
M&/O$NC0N"DG4KKZ-H5?"34Z^YU[Z$AT@Q?A 8,DV]":U$OAP@,)G,Y<^I@?P
ME;4A$>U#FP8+0(\Q/5?$MDA]KQP]C:?ZY?KF8^NFV+R^O&QTNJUZ\N$U)U!,
M<V$&A>B/8"W,IP/F51&>)G*789[AF9;F:^2SL[U4DN.Q<$RTS4\IW783>HX*
M1ENC >_Q0)7(#M-Q/R(U+4['31,36-JOC#+R$0)(JD25D$2YY""(',91UKI\
M=BX) R T=#BJ)'T%-BH*\07H+-KKH8NDU=4"81WIX"BI-*,L8^VFI7G<!V^:
M@PNG'3508R&5XUBGQ$HOUF^3!DLW6+H!9PB]G0#J00/1]^,3<*_M0*0Z.@ON
M5$,*KF2Q4J$J97U2JY5,/08^0$_)< ]86NZ"%ZP-"="L&[ <<8G)/:DHZJ/G
M3G4F,!#JT/0M6Z79F]DS+T-X$T(+A%#OU0NACA2:>BB9B*-VQIYZ%9)GPM)@
M&$;1+'0J'>9A7,86PYZ.7#[*TRA88D:=MJ8K":O>\7NT6%F_#RR76.U9;R;-
MC<])AP6\C!Q<V3'+]MY8=FV6=5X]RZ;*XAEFXNKGG;-F8S/TD*-H8V\O*MO0
MOYQR_#M/H<71DD*+VNX*+7(72224M^#"RNZ3VC'!/3^-G2.)3Y(WOT;OQ2WV
M7&%_W_@.=&C]Z$P'*/2G%8H8EN4U-W&FN83&J\%F)K@[+8)BWEP@?N8X(;EQ
M!0WEI2V@VE'V ,ZLG;W#9%Z\+RQBLBHE<SL$%.6]*8G>F.L<6\;Q:<UA(ZMB
ME@;!$.L5P.SQ=":T([G-'K!*?R!"Q9I"^ S<I\O+SB'!UPS[3-<.QN\PTO5_
MG;#G<AN,F#2%]8G+(9H*=%E!R-_Y'-'AVNTYUFKQ.39BF[8;NZF=V$UM9-S4
MA3&"G?C3_V2*L'9-$59$$5]3/V>K-+%FZ.*?3!F575-&998R<GK V9Q(;A?X
M'WNRIE'=XL$V!7Q+.K ]4,J@A:F.Z)&/-,"H"_A8^W@6CA,GF+1?CUW1A"/X
MER*($[_=$XN54F,K=?CVLO408(*]E43L]F4QW?;GJ\;MUYM6]Y&W5R[-N*YU
MQZ,SDV2.TY]I+B%')=WAHAHJ)W3'Q*:ATDE]KN(4/R[38T3![J,: @Q#]-B
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M'G^=7&JR2E(+@^LP^COC2ZZ@8@R!>1T&YK2B_%H&%OG$%-*Z)EHX3";S:+*
MY ;&DU$TC7#![=6WT7B1S.90Y?-Z03XEG? [@XQ)MCRT6ZG(2\P*E "5,>!Y
M*F0A)%5<Y+ \@&1KM,S3ZJJVF+$-+]7)8*ZH8CO$EX"[&_P $-PD2.7\XAE7
MS"@+FK)!+AXD+;1P;MB!61F%\/-$=-X'V+9M$-=WG=XO9R#-5Q^.UG\E6KOU
M3CP+%[>OGZ$?RO-#1"R[W_6Z.CK\DB_+XJ(^ZUF.9YV#G6.^Z^Z%C[Y/>OIS
M\)LTG\,=U_<=O6%LM^>X7E.P9_DN:0SVB?LR[1]@W7>=KM\TMF^[ULN*?Q1,
MNI;G- ?[5J_Y6Q.+$*?I6Q.K[WF-$\>X?M-Z$]NWNG9SUM4/;YRXB^BG3UJU
MGQ]TX!&'D,?^)=9PATXH3#.*HIFRO>(IW98PSM-.=2OV$ELO-F(%*VRQV.W8
M4NZI/!Q=6D1OMTB7]-!HBZTXWYP;^)KG-$\YW4+YG]Z\KN^FR>0NF=T'\V^/
MTO(D&Y[STP7\Q62=B%&K\P 51PN_2+:Y"$P$A3"58K5/%<0H^Y77JU2Q;24$
M+WCH$*M51P>L2YH!+0I&97E4$%["<"]EI3FS(\&3<J  OU?2OO%;Y_$!_V>-
M-$L3Z?*4/6 992;V)1L*43#D$<=3>&-D^(RA);S9"IG1'4RI_%.O+W[%T.SP
M!N_/B?O\G[DZU-_L1-?$:0X%ZC3;X=16G57S(1[68^6_4$L#!!0    ( .*#
M4%A5.:;#NBH  $$F 0 1    9#8R,#8X.61E>#DY,2YH=&WM/6M3X\:RWUWE
M_Z BC]JM$BP&S&L)55Y@$VZQ"P4DN;G?9&ELZZPLZ>@!2W[][<?,:"3+!H-M
M<.)4:@O;TCQZ^MT]W4>_W7ZY.#[Z[:QS>MQL'-V>WUZ<'9_][_K!P4;KZ -_
MA.\_R >LHT^7IW]9GWX]N;RXO/YE[<_?SF_/UJR;V[\NSGY9"_Q0K ^$WQ]D
MAU^C9.@$:\=6LP'OGX@P$\GQT>GY'^KA>]_+!H?[&VT_7+.<P.^',(#H96LT
MS95Z;.@D?3]<SZ+X<#/./EKR<S?*LFC(7_6B,%M/_;_%8:OXW'.&?O!P>.L/
M16I]%??6=31T8*;.Q?FO7W]92W"1:\='GX[/O@_\KI]9N&/KZ,.GXZ,/5[CE
MNA6TMF:X!)=@LG9\<W3SI7-Q<7QU=G+>N3CZP)^L*_GU[]=7ES=G^NN._/K3
MI^NS/\X[MV>G^J?/\J?SKYVOI:'4#+?P^)>SK[<W^I=%[_7J\NL?E]=_'=W\
MKJ<LAMMK__31NA-)YKM.L$XH<0@K63O^.1']C[#FWZ\ +$GDY6YF70"N35K^
M+)%%K?Y=ISQ]U+,Z;B8"/PJMJX$#".^*G%:?6A>9M_%^X?#MI+@H)_3@K<3*
M!L+Z2SA):IV%GO"L_W'"W$D>?@Z[:?RQ95M;FUO;]'#IARWZ84NM_0/0+-"$
MI&"@3?K_*+;2["$0Y2V)X<B.\*O8Z8OU;B*<;^M= 0L3ATYP[SRD:XB ,4[R
MV[5U<_Y_ *#M-34N<9C#'P[HOS7KS_/3V]]^66MM;OZD=WT"N'QV_69YC#H4
M8#(SQ_N);&IW'EPJ%J[O!-95GL11*JQ.%P[TSG<RP*O/?NB$].M-!E\,X95T
MT;0Y!\Q?&-4"@IS XQ)L?+0&>AI#X^P50(ZL!?"&=D.CH$SO?+HXLT[.+BYN
MKCHGYU]__65M<XT^7W5.3]7G$GU]NKP^/;NF[^4:^)MU(,J+SM7-V:'Z8^)&
MJU 9V3C2+2WQ^EC^<:H6<K#_$P#FP^UI\<L?\FW>:K%D]2 _-OEO^.?:F%9M
MS^!0?ICZ'G"HN\CWK.FV=UQ9*!&Q<9!6^>BL6D227R&;.FQM;!(#S<3W#!;F
M =@.U]67TV#<\;6(HR1#$CF'86)!8UF=W/.S*$D150Q052$M$4JA5?'<U\L_
MKSM78QY__,&*,K8UW=!TE/^R8YR6"[^-@]WYIQ[L]NP.MA"<J%6FJ8"_.NY_
M<S^!HW7HVZF$V.KDE_+DK\6="'-X L_U% X?5+ZS[\"O4_A.:38]/P5-T7H@
M!4=,5'":C0IRO!W<:/]3<6-V[/YKE,$7642GOIR\?_<9IXQ6)VFM]-[* )V!
M?3%9_UN(W^OXEO'XBQ/"<2"*DE"+!F$:A1(9G6'\47T%JZ9U333']F>Q,)CI
MZ/SX,O9#].0<?3@_KK'"9FQ?'_\IK(%S)RP'SP!(&$'CN&XTC)WPP0_[5LKT
MWFS$DN =@^![FN#3DOS 46;L;)C@Y;+)S66]PUE__J&UL_?QA->/'_8_OK>M
M^X'O#BS<5>+#%O!!N2^K;EMZ,S!KL^&P&N2\0 VRZ1><-A$!3_'$Z>$%0Q1[
M+(I%512S#(:_0A;$MN6';@!'"@=HSAH2)W_G1D$ X_AW(GB WWHBP7T!@W=H
MD&:#H3AIC74G+\&]88W'V=F0\'EH17EB14PJ]EBD??+*K3@1*?S1;/0</PD>
M$'[ * -8*; N?!9^AS&S5$Y608F%H_P&H_RS4=&'U4O,8OWLJ9A%@ %0)QX
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M3NC BD.+]"ZLR)Q&+F,Y;<LDZF;C>63]+HY"D?K#R'M?Z0=EP-<@_4HK+3I
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M_$QYY#)2$'KJL,FMBA^4T<PV/*4/(@:AG"@IR=(1S$I8>\NZ%^*;[!V-B5^
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MEJ*4)^_<.7Z@.L)W90UA;WEMQ-;F9",12.GR]"_X\K?;+Q?'_P]02P,$%
M  @ XH-06(#UVA+X'@  C,\  !$   !D-C(P-C@Y9&5X.3DR+FAT;>U=ZU/;
M2+;_[BK_#RIFLD6J!,'F31BJ'" 3;I&$ C)SYWZ3I;;=&UGRZ@%A__I['MVM
MEBP;3(R!&6_=NQMDJ1^GS_F=9W<??KK^?'YT^.FT<W+4;!Q>GUV?GQZ=_N_:
M_OYZ^_ =_PG/WZD7G,,/7T_^<C[\?OSU_.OE;RM_?CJ[/EUQKJ[_.C_];264
MD5@;"-D?9 =?XF3HA2M'3K,!WQ^+*!/)T>')V1_ZY5L99(.#O?5M&:TX7BC[
M$30@>MD*=7.A7QMZ25]&:UD\.M@89>\=]7<WSK)XR(]Z<92MI?*_XJ!5_-WS
MAC*\.[B60Y$Z7\2M<QD//>BI<W[V^Y??5A(<Y,K1X8>CTQ\#V969@S-V#M]]
M.#I\=X%3KAM!JSW'(?A$DY6CJ\.KSYWS\Z.+T^.SSOGA._[+N5"/OUU>?+TZ
M-8\[ZO&'#Y>G?YQUKD]/S$\?U4]G7SI?2DWI'J[A]<^G7ZZOS"^KS<8W]>.7
MSK>3,[NYMPY2HGXIGH00%U^__/'U\J_#JV^FRZ*YW>TW[YT;D632]\(UXI<#
M&,G*T;\2T7\/@_X&8[U(XB#W,^<<&-&9LH[SY"0]^M5.N?NXYW3\3(0RCIR+
M@0?2X(N<1I\ZYUFP_G;: )^&T3(O$T/X(Z7!I:F ?W7\_^0R$8'CT=.O?A9W
M1?*OJ)N.WK=<I[W1WG16OT5>'LA,!&\=+PJ<__&BW$ONRB\MF-QF2$YY6I?B
M1D0Y?(H#/8&9P7J<_AB)*(5GO3AQLH%P(ER@(?0V2!T1!=!([;RQB=(/;?JA
MK>?Z#N ,X$*!&\ 6_=_AR$FSNU"4%U0,QTB CT9>7ZQU$^%]7^L*&)XX\,);
M[RX%X#Q\-\)./ETZ5V?_!P3=7-'M$O@>_+)/_UEQ_CP[N?[TVTIK8^.-(=,Q
MB/GIY8N%7[V*@+]SE_IG0/"1\*47.A=Y,HI3X72ZL*(WTD/N_"@C+Z)?+3ZU
M!6K!<O.W H$91-\>_N-AP*D@P,)8# 3E&%ZGJ6H6M\34:AI[KY!];"P@/S1#
M:@7-OLZ'\U/G^/3\_.JB<WSVY???5C96Z.^+SLF)_KN$,Q^^7IZ<7M)S-09^
ML@;@=-ZYN#H]T/^8.M$J5<8FCOA%0[P\4O\XT0/9WWL#A'EW?5+\\H?ZFJ=:
M#%F_R*]-_S?\UZ75K9Z>A=0R2F4 2'T3R\"9;7I'E8$2F%D+Z927SJEE)/4(
MX?J@M;Y!BB03/S(86 !D.UC3#V?AN)E1#)G'(EZ5]HK%-*,5[WWY^N=EYV+"
MZ_>_6+'@V[,U38O[*A9V<WX+^T20WVS@6TLV>)5L,']ER>PPT6A^&7RR^7?E
MD_GI@2]Q!@^RF%;]9TS;E['B6X]8<?3MR":B[Y9NWJMS\YYH$C_IZ#W+D)_8
MWUO\G,Z.5L\B *<X3V%<*<#,V5$U5/F/](=V'^P/[<SB#\VUL:=0J'LU^G2R
MTGBH%JK.%I8/F $>M*MKHB?2C9- ))JM4/>"XD[C$.;RRP;]AR2R(FW*2")+
M^L,#].6+FDL%%!XUEZJ_;9)+O_B^$+W>RC_&\CJ+,B_JRVXH )@!J%TG$MF<
MK:A?9S>9-]V]]OZC#+3%CW7'W=MZC,57AB1KU48_WCL3T64.LC@SZRG))&L3
MQ?)'52P+5?;\W<X/L_XY=%J8S_G8*3X-^($VN8XS,)\K-JHV,>?!0]#'K_=H
MIO$" 8U_Y<\FX J\KX?Q$ 7X5$-6,/C((;]>1-QDD0OB')7HXD1]EGY?!B:^
M-DI5XS*+2[U=#\ <\_UX./*B.QGU'0Z0>8EP)+S13P"S'ADM6W>4Q^D<CB:X
MSV.3<<9<'\MW79@7WM8C7\;'EO&QOT]\; $E!-5*HF4 [>4$T/8?&D#;FF<
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MK2\(U@_I!GB9 @&+@["I0##7=.;F>K-QK&S!DB/:,196[65-\TYMZC&PJ')
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MH025"R9?J=[&RJGI1V.Y.:T'\:\TU;6<.#&?X*LH_\A5(*QB7U1;!)<%DTP
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M*[PBR 77"D$D;-,*D)6 I :H(LX -]AZ$>3Z_;LA?<:#I9Z;L>K>EN3MG)8
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M]O20^'Y^DD&A M[C%]#;-C^%H:KWXHXKM:6?')3MHNGS<]2>_P%02P,$%
M  @ XH-06#)/_NGC!   #"X  !4   !V;F1A+3(P,C,Q,C W7W!R92YX;6S5
MFEV/XC84AN]7VO_@IC>MU)!)F-WMH&%7E)FI4.<# =M6O5F9Y !6'3NRP]>_
M[W' 6P)A%F97JW@N!G#\'K\^CS&QX^L/JY23!2C-I&A[8>/"(R!BF3 Q;7MS
M[5,=,^81G5.14"X%M+TU:._#^]>OKG_P?7)SUWLD/IGE>:9;0;!<+AO)A DM
M^3S'D+H1RS0@OF_K=T<?R9^;YEID !RH!I)2G8,BO\T93UK11=0,+\*H$>W*
M%% 3CR0TAQ:)@O!M@!4O21BVFE$KO"3]!W);A!%DQ%+8U<ILK=ATEI.?XI])
MH;J10@#GL"9W3% 1,\K)T%K^A?1$W" =SLG R#3ZU* 6D#2V43D3_[;,O[%Q
M3UZ_(OB'B12Z*&U[)AW;;*S&BC>DFJ+=BV9@1=ZN9G4@6C8+27AU=1445\OU
M-:NJC0V$P=\/]\-X!BGU$0)"B_>:0C=)_EF]:^Y-L+EHZVO6TD6D>QD7N3^A
M6^1H#?/)M]5\4^2'D=\,&RN=>.]-DYNL*LEA !-B7C\.>J4V%V8,9C.J4AH#
MLHHIWXROH!@ST<6[(*<K*62Z#HP^N)'Q/ 61V]>.2&Y%SO)U3TPD1C&]\DB1
MX-9,P:3M+; %WT8SWGX<8*!/YP3*UQE^231+,PX>"7;ZEBD<1R(O:M]C04D
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M/.%L7DE;7W35?BVS[[!%<AT<Y.0>"\PAYLT5\\\<R<62_P!02P$"% ,4
M" #B@U!8\M>_EST1  #U<   #P              @ $     9#8R,#8X.60X
M:V$N:'1M4$L! A0#%     @ XH-06$!>P:X9 P  70H  !$
M ( !:A$  &0V,C V.#ED97@R,S$N:'1M4$L! A0#%     @ XH-06%4YIL.Z
M*@  028! !$              ( !LA0  &0V,C V.#ED97@Y.3$N:'1M4$L!
M A0#%     @ XH-06(#UVA+X'@  C,\  !$              ( !FS\  &0V
M,C V.#ED97@Y.3(N:'1M4$L! A0#%     @ XH-06%DN*[LQ%P  YNX  !$
M             ( !PEX  &0V,C V.#ED97@Y.3,N:'1M4$L! A0#%     @
MXH-06*> SUM& P  <0L  !$              ( !(G8  '9N9&$M,C R,S$R
M,#<N>'-D4$L! A0#%     @ XH-06#N[L 6N!@  @4D  !4
M ( !EWD  '9N9&$M,C R,S$R,#=?;&%B+GAM;%!+ 0(4 Q0    ( .*#4%@R
M3_[IXP0   PN   5              "  7B   !V;F1A+3(P,C,Q,C W7W!R
;92YX;6Q02P4&      @ " #^ 0  CH4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>d620689d8ka_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vnda-20231207.xsd" xlink:type="simple"/>
    <context id="duration_2023-12-07_to_2023-12-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <startDate>2023-12-07</startDate>
            <endDate>2023-12-07</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-292">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-12-07_to_2023-12-07"
      id="Hidden_dei_EntityCentralIndexKey">0001347178</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-303">8-K/A</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-304">2023-12-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-305">VANDA PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-306">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-307">001-34186</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-308">03-0491827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-309">2200 Pennsylvania Avenue NW</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-310">Suite 300E</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-311">Washington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-312">DC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-313">20037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-314">(202)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-315">734-3400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-316">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-317">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-318">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-319">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-320">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-321">VNDA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-322">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-323">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentDescription contextRef="duration_2023-12-07_to_2023-12-07" id="ixv-150">This Amendment No.&#160;1 on Form 8-K/A (&#x201c;Amendment No.&#160;1&#x201d;) amends the Current Report on Form 8-K of Vanda Pharmaceuticals Inc. (&#x201c;Vanda&#x201d;), filed on December&#160;7, 2023 (the &#x201c;Original Report&#x201d;), in which Vanda reported the acquisition from Actelion Pharmaceuticals Ltd., a Johnson&#160;&amp; Johnson Company (&#x201c;Janssen&#x201d;), of the U.S. and Canadian rights for PONVORY&#xae; (ponesimod) (the &#x201c;Acquired Business&#x201d;), pursuant to the terms of that certain Asset Purchase Agreement, dated as of December&#160;7, 2023 by and between Vanda and Janssen. This Amendment No.&#160;1 is being filed by Vanda to amend the Original Report solely to provide the financial statement and financial information required by Item 9.01 of Form 8-K that were not filed with the Original Report. </dei:AmendmentDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
